Risk for Venous Thromboembolism in Carriers of the Factor V Leiden Mutation
Authors: Saskia Middeldorp, Harry R. Bller, Martin H. Prins
Journal: Annals of Internal Medicine (2003)

Letters7 January 2003Risk for Venous Thromboembolism in Carriers of the Factor V Leiden MutationSaskia Middeldorp, MD, Harry R. Bller, MD, and Martin H. Prins, MDSaskia Middeldorp, MDAcademic Medical Center; 1100 DE Amsterdam, the Netherlands (Middeldorp, Bller)Academic Hospital Maastricht; 6229 HX Maastricht, the Netherlands (Prins)Search for more papers by this author, Harry R. Bller, MDAcademic Medical Center; 1100 DE Amsterdam, the Netherlands (Middeldorp, Bller)Academic Hospital Maastricht; 6229 HX Maastricht, the Netherlands (Prins)Search for more papers by this author, and Martin H. Prins, MDAcademic Medical Center; 1100 DE Amsterdam, the Netherlands (Middeldorp, Bller)Academic Hospital Maastricht; 6229 HX Maastricht, the Netherlands (Prins)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-1-200301070-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:For our prospective cohort study of asymptomatic carriers, we by definition excluded relatives with previous venous thromboembolism. However, the symptomatic carriers of the factor V Leiden mutation actually were represented as the group that had had an outcome event in our earlier retrospective family study (1), in which all relatives were included. We observed virtually the same absolute yearly incidence in our earlier study as in our prospective study (0.45% [95% CI, 0.28% to 0.61%] vs. 0.58% [CI, 0.26% to 1.10%]). Since these incidences are much lower than the known major bleeding risks associated with the prophylactic use ...References1. Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyk K, van der Meer J, . The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128:15-20. [PMID: 9424976] LinkGoogle Scholar2. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Brit E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993;153:1557-62. [PMID: 8323419] CrossrefMedlineGoogle Scholar3. Nordstrm M, Lindblad B, Bergqvist D, Kjellstrm T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-60. [PMID: 1506812] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Saskia Middeldorp, MD; Harry R. Bller, MD; Martin H. Prins, MDAffiliations: Academic Medical Center; 1100 DE Amsterdam, the Netherlands (Middeldorp, Bller)Academic Hospital Maastricht; 6229 HX Maastricht, the Netherlands (Prins) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism Saskia Middeldorp , Johan R. Meinardi , Maria M.W. Koopman , Elisabeth C.M. van Pampus , Karly Hamulyák , Jan van der Meer , Martin H. Prins , and Harry R. Büller Risk for Venous Thromboembolism in Carriers of the Factor V Leiden Mutation Rebecca L. Orwoll Metrics 7 January 2003Volume 138, Issue 1Page: 76-77KeywordsEstrogensFactor V LeidenForecastingHemorrhageProphylaxisProspective studiesRetrospective studiesThrombosisVenous thromboembolismVitamin K ePublished: 7 January 2003 Issue Published: 7 January 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...